Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pentoxifylline as Add-On Therapy for Mild-to-Moderate Plaque Psoriasis
NCT07626788Not yet recruiting
- Start
- Nov 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Randomised, double-blind trial in plaque psoriasis comparing Pentoxifylline Add-On Therapy with Placebo Add-On Therapy (2 arms). Primary endpoint: Proportion of Participants Achieving Psoriasis Area and Severity Index 50 at 12 weeks. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pentoxifylline
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT07626788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07626788.